61955-82-6Relevant articles and documents
Synthesis, structure, and reactivity of Pd complexes with mixed P,S-Bis(ylide), ylide-sulfide, and ylide-methanide ligands
Serrano, Elena,Soler, Tatiana,Urriolabeitia, Esteban P.
, p. 2129 - 2138 (2013/06/26)
The coordination properties of the ylide-sulfonium salts [Ph 3P=C(H)COCH2S(R1)R2]X [R1 = R2 = Et, X = Br (2); R1 = Me, R2 = Ph, X = ClO4 (5)], the phosphonium-sulfide salt [Ph3PCH 2COCH2SEt]Br (3) and the neutral ylide-sulfide [Ph 3P=C(H)COCH2SPh] (4) towards PdII have been studied. Four different bonding modes have been characterized. The reactions of the ylide-sulfonium salts 2 and 5 with PdCl2(NCMe)2 and NEt3 afford the chelating bis(ylide) complexes cis-[PdCl 2{Ph3PC(H)COC(H)S(R1)R2-κC,C}] [R1 = R2 = Et (6); R1 = Me, R2 = Ph (7)], which are obtained selectively in the meso form (RS/SR). This bonding mode is characterized, including by X-ray crystallography, in the acetylacetonate (acac) complexes [Pd(acac-O,O′){Ph3PC(H)COC(H) S(R1)R2-κC,C}]ClO4 [R1 = R2 = Et (8); R1 = Me, R2 = Ph (9)], which were obtained by reaction of the respective precursor 6 or 7 with AgClO4 and Tl(acac). On the other hand, the C,S-chelating bonding mode has been characterized in [PdCl2{Ph3PC(H)COCH2SR- κC,S}] [R = Et (10); R = Ph (11)], obtained by reaction of the phosphonium-sulfide salt 3 with PdCl2(NCMe)2 and NEt 3 or by reaction of the ylide-sulfide 4 with PdCl2(NCMe) 2, respectively. Furthermore, the tridentate bonding mode μ-S:κC,C,S has been determined in the dinuclear derivative [PdCl{Ph3PC(H)COC(H)SPh-μ-S:κC,C,S}]2 (13), synthesized by reaction of the ylide-sulfide 4 with PdCl2(NCMe) 2 and NEt3. Compound 13 reacts with PPh3 to afford the κC,C-chelate [PdCl{Ph3PC(H)COC(H)SPh-κC,C} PPh3] (14) after cleavage of the sulfide bridge. Compound 14 was obtained as a single diastereoisomer, which was characterized as the D,L form (RR/SS). Copyright
Diarylalkanoids having activity as lipoxygenase inhibitors
-
, (2008/06/13)
The present invention is novel diarylalkanoids having activity as lipoxygenase inhibitors, novel pharmaceutical compositions therefor, and novel methods of use in treating asthma, allergies, cardiovascular diseases, migraines, psoriasis and immunoinflammatory diseases for diarylalkanoids. The compounds of this invention are also useful as cytoprotective agents.